Search

Your search keyword '"Bonin, Randi"' showing total 8 results
Start Over Author "Bonin, Randi"
8 results on '"Bonin, Randi"'

1. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis

Author

Dougados, Maxime, Maksymowych, Walter P, Landewé, Robert B M, Moltó, Anna, Claudepierre, Pascal, de Hooge, Manouk, Lambert, Robert G, Bonin, Randi, Bukowski, Jack F, Jones, Heather E, Logeart, Isabelle, Pedersen, Ron, Szumski, Annette, Vlahos, Bonnie, and van der Heijde, Désirée

Published
2018
Full Text
View/download PDF

2. Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Author

Dougados, Maxime, van der Heijde, Désirée, Sieper, Joachim, Braun, Jürgen, Maksymowych, Walter P., Citera, Gustavo, Miceli-Richard, Corinne, Wei, James Cheng-Chung, Pedersen, Ron, Bonin, Randi, Rahman, Mahboob U., Logeart, Isabelle, Wajdula, Joseph, Koenig, Andrew S., Vlahos, Bonnie, Alvarez, Daniel, and Bukowski, Jack F.

Published
2014
Full Text
View/download PDF

4. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis

Author

Dougados, Maxime, primary, Maksymowych, Walter P, additional, Landewé, Robert B M, additional, Moltó, Anna, additional, Claudepierre, Pascal, additional, de Hooge, Manouk, additional, Lambert, Robert G, additional, Bonin, Randi, additional, Bukowski, Jack F, additional, Jones, Heather E, additional, Logeart, Isabelle, additional, Pedersen, Ron, additional, Szumski, Annette, additional, Vlahos, Bonnie, additional, and van der Heijde, Désirée, additional

Published
2017
Full Text
View/download PDF

5. Effects of Long‐Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104‐Week Results From a Randomized, Placebo‐Controlled Study

Author

Dougados, Maxime, primary, van der Heijde, Désirée, additional, Sieper, Joachim, additional, Braun, Jürgen, additional, Citera, Gustavo, additional, Lenaerts, Jan, additional, van den Bosch, Filip, additional, Wei, James Cheng‐Chung, additional, Pedersen, Ron, additional, Bonin, Randi, additional, Jones, Heather, additional, Marshall, Lisa, additional, Logeart, Isabelle, additional, Vlahos, Bonnie, additional, Bukowski, Jack F., additional, and Maksymowych, Walter P., additional

Published
2017
Full Text
View/download PDF

7. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

Author

Maksymowych, Walter P, primary, Dougados, Maxime, additional, van der Heijde, Désirée, additional, Sieper, Joachim, additional, Braun, Jürgen, additional, Citera, Gustavo, additional, Van den Bosch, Filip, additional, Logeart, Isabelle, additional, Wajdula, Joseph, additional, Jones, Heather, additional, Marshall, Lisa, additional, Bonin, Randi, additional, Pedersen, Ron, additional, Vlahos, Bonnie, additional, Kotak, Sameer, additional, and Bukowski, Jack F, additional

Published
2015
Full Text
View/download PDF

8. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.

Author

Maksymowych, Walter P., Dougados, Maxime, van der Heijde, Désirée, Sieper, Joachim, Braun, Jürgen, Citera, Gustavo, Van den Bosch, Filip, Logeart, Isabelle, Wajdula, Joseph, Jones, Heather, Marshall, Lisa, Bonin, Randi, Pedersen, Ron, Vlahos, Bonnie, Kotak, Sameer, and Bukowski, Jack F.

Subjects
SACROILIAC joint, RESEARCH, TIME, RESEARCH methodology, MAGNETIC resonance imaging, EVALUATION research, MEDICAL cooperation, ANTIRHEUMATIC agents, SEVERITY of illness index, TREATMENT effectiveness, SPONDYLOARTHROPATHIES, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, QUESTIONNAIRES
Abstract

Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).Methods: Patients meeting Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, but not modified New York radiographic criteria, received double-blind ETN 50 mg/week or placebo (PBO) for 12 weeks, then open-label ETN (ETN/ETN or PBO/ETN). Clinical, health, productivity, MRI and safety outcomes were assessed and the 48-week data are presented here.Results: 208/225 patients (92%) entered the open-label phase at week 12 (ETN, n=102; PBO, n=106). The percentage of patients achieving ASAS40 increased from 33% to 52% between weeks 12 and 48 for ETN/ETN and from 15% to 53% for PBO/ETN (within-group p value <0.001 for both). For ETN/ETN and PBO/ETN, the EuroQol 5 Dimensions utility score improved by 0.14 and 0.08, respectively, between baseline and week 12 and by 0.23 and 0.22 between baseline and week 48. Between weeks 12 and 48, MRI Spondyloarthritis Research Consortium of Canada sacroiliac joint (SIJ) scores decreased by -1.1 for ETN/ETN and by -3.0 for PBO/ETN, p<0.001 for both. Decreases in MRI SIJ inflammation and C-reactive protein correlated with several clinical outcomes at weeks 12 and 48.Conclusions: Patients with early active nr-axSpA demonstrated improvement from week 12 in clinical, health, productivity and MRI outcomes that was sustained to 48 weeks.Trial Registration Number: NCT01258738. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results